Chami

Healthcare Affordability Must Be Paired with Investment in Diagnostic Infrastructure – PTA’s response to the 2026 Federal Health Budget

Healthcare Affordability Must Be Paired with Investment in Diagnostic Infrastructure – PTA’s response to the 2026 Federal Health Budget   “Diagnostics inform 70% of medical decisions. Without investment in the pathology services, technology, and infrastructure that enable accurate, timely diagnosis, we risk creating a bottleneck where patients can afford to see their GP but can’t […]

Healthcare Affordability Must Be Paired with Investment in Diagnostic Infrastructure – PTA’s response to the 2026 Federal Health Budget Read More »

Australian Genomics Update 

Australian Genomics Update  PTA participates in regular discussion and updates with Australian Genomics  Commissioner Tiffany Boughtwood, and Director Renaye Lucchese.   Here is an update of the current state:  Australian Genomics is setting the vision for health genomics in Australia for the next 10 years. By 2035 Australian Genomics foresees genomics transforming healthcare to focus on prediction, prevention, early diagnosis and personalised management of targeted treatment.  They have developed

Australian Genomics Update  Read More »

New Licensing Agreement Supports a Maturing Clinical Genomics Infrastructure Landscape.

New Licensing Agreement Supports a Maturing Clinical Genomics Infrastructure Landscape. A recently announced licensing agreement between Genomical and Illumina – two PTA members – signals support for the broader shift in how clinical genomic laboratories are approaching workflow integration and data management. For accredited clinical laboratories, timely rollout of new genomic tests can be supported through

New Licensing Agreement Supports a Maturing Clinical Genomics Infrastructure Landscape. Read More »

New National Framework for Chronic Diseases 

New National Framework for Chronic Diseases  11 March 2026  Health Minster Mark Butler announces an investment of $110 million over three years on projects that help prevent chronic conditions. This funding forms part of the newly launched National Strategy Framework for Chronic Conditions 2026-35 (NSFCC).  Over half of all Australian have at least one chronic condition and about 24% have

New National Framework for Chronic Diseases  Read More »

Tough Federal Budget – signals austere times for healthcare 

Tough Federal Budget – signals austere times for healthcare  25 Feb 2026  The Age and SMH report  “no nice-to-haves” in Prime Minister Anthony Albanese’s demands for budget austerity, stating that ministers need to find billions in savings for the May budget. https://www.theage.com.au/politics/federal/no-nice-to-haves-albanese-demands-ministers-find-billions-in-savings-for-may-budget-20260224-p5o53t.html  In discussions with the commonwealth Department of Health Disability and Aging (DHDA), PTA has heard that there is no new money

Tough Federal Budget – signals austere times for healthcare  Read More »

PTA Member Nutromics publishes important study in Nature Biotechnology

PTA Member Nutromics publishes important study in Nature Biotechnology    PTA member and Australian Innovator Nutromics are pioneers in the wearable and skin patch diagnostic technology space.   A pilot study of their electrochemical aptamer-based patch for continuous drug monitoring was recently published in Nature Biotechnology. See below for details.  Nutromics are based in Melbourne and have been a members of PTA for

PTA Member Nutromics publishes important study in Nature Biotechnology Read More »

Importance of diagnostic testing in the management of Antimicrobial Resistance (AMR). 

Importance of diagnostic testing in the management of Antimicrobial Resistance (AMR).  Feb 23 2026  Australia’s CDC has just published the Aura Report, the sixth Australian report on antimicrobial use and resistance in human health.  Here is a link to the full report.  AURA REPORT – Sixth Australian report on antimicrobial use and resistance in human health  In

Importance of diagnostic testing in the management of Antimicrobial Resistance (AMR).  Read More »

Same root cause, different impact – HTA PBAC and MSAC have passed their use by date 

Same root cause, different impact – HTA PBAC and MSAC have passed their use by date  10th February 2026  This week the ABC reported on the lack of PBS funding for some commonly used medicines. See the link below for the full article.   Essentially the issue boils down to the same root cause as we find for

Same root cause, different impact – HTA PBAC and MSAC have passed their use by date  Read More »

PTA CEO Calls for Urgent Healthcare Reform as Policy Reviews Stall 

  Dean Whiting warns Australia has a narrow window to implement systemic change before healthcare becomes unsustainable  January 2025 – Pathology Technology Australia (PTA) CEO Dean Whiting has delivered a sobering assessment of the healthcare sector’s trajectory, warning that critical policy initiatives have stalled despite the government’s return to office earlier this year.  Speaking with Health

PTA CEO Calls for Urgent Healthcare Reform as Policy Reviews Stall  Read More »

Joint Statement on the Commencement of Genomics Australia

Joint Statement on the Commencement of Genomics Australia Pathology Technology Australia and the Industry Genomics Network Alliance (InGeNA) warmly welcome the formal establishment of Genomics Australia as a national body under the Department of Health and Aged Care from 1 July. We commend the calibre of the Genomics Australia leadership team, which brings together deep

Joint Statement on the Commencement of Genomics Australia Read More »

Scroll to Top